CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease
If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPA
Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...
Pharmabiz14h
EU committee recommends approval of AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca, global, science-led biopharmaceutical company, announced that its Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult ...
Renal & Urology News23h
FDA Approves Fasenra for Eosinophilic Granulomatosis With Polyangiitis
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.